Contract Research Organization (CRO) and Healthcare Intelligence Services
Strategic Profile
With approximately 88,000 employees in over 100 countries, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA was named to the Fortune World's Most Admired Companies List, ranked No. 1 in its sector for the fifth consecutive year in January 2026. The company maintains market leadership through its integrated suite of services spanning research & development, real-world evidence generation, commercial analytics, and contract sales solutions.
Cyborg Score Rationale
IQVIA generated $16.3B in trailing twelve-month revenue and maintains a $30B market cap as of February 2026. The company demonstrates operational resilience with strong backlog conversion capabilities and strategic investments in AI integration across its service offerings.
Top Insights
IQVIA ranked #1 in Fortune's Most Admired Companies for its sector for five consecutive years, reflecting strong operational execution and market respect
Company acquired Throtle in November 2025, demonstrating continued M&A strategy to enhance technology and data capabilities
Real-world evidence (RWE) and AI integration are key strategic priorities, addressing pharma industry shift toward more efficient clinical development models
Three-segment structure (Technology & Analytics, R&D Solutions, Contract Sales) provides diversified revenue with exposure to both clinical development and commercialization phases
Named Competitors
Syneos Health — Full-service CRO and commercialization solutions provider
Labcorp — Integrated drug development and laboratory testing services
Charles River Laboratories — Preclinical and clinical laboratory research services